1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Neuroendocrine Carcinomas (NEC): new trials by email Literature Review of Neuroendocrine Carcinomas (NEC) trials Research Report on Neuroendocrine Carcinomas (NEC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 203 | 2023-09-05 | 2026-07-15 |
Carcinoma, Neuroendocrine (1) · Lung Neoplasms (1) · Small Cell Lung Carcinoma (1)
Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1)
EC regimen (1) · Irinotecan (1) · PM 01183 (1) · Paclitaxel (1) · Pharmaceutical Preparations (1) · Topotecan (1) · atezolizumab (1)
United States (1)